What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?

Mehanna, Joe; Haddad, Fady G.; Eid, Roland; Lambertini, Matteo; Kourié, Hampig Raphaël

doi:10.21037/tcr.2018.09.07

Cited by 1 publication

(1 citation statement)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pertuzumab is a monoclonal antibody that targets HER2 and functions in a way that complements the effectiveness of trastuzumab. Pertuzumab works by inhibiting heterodimerization her2-4 while trastuzumab blocks her2-2 [33,34]. An effective technique for adjuvant treatment is dual anti-HER2 blocking with trastuzumab + pertuzumab.…”

Section: The Function Of Monoclonal Antibodies In Breast Cancer Thera...mentioning

confidence: 99%

A Review of the Advancements in Targeted Therapies for Breast Cancer

Jallah,

Dweh,

Anjankar

et al. 2023

Cureus

View full text Add to dashboard Cite

Breast cancer, the second-most common and lethal disease in women, poses a severe danger to global health. Breast cancer rates continue to climb despite advances in medical technology. Predictions indicate that by 2040, there will be more than three million new cases yearly. Targeted medicines have experienced a profound transformation in treating breast cancer, allowing for individualized strategies that lessen side effects and improve patient outcomes. This thorough analysis gives a rigorous investigation of current developments in breast cancer-targeted treatments. It carefully examines several subtypes, including hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), recognizing the illness' fundamental variety. It offers specialized treatment plans catered to each subtype's particular traits. The review also examines how precise genetic abnormalities like BRCA1/2 and PIK3CA mutations and molecular profiling facilitate therapy selection. Monoclonal antibodies and small molecule inhibitors are some of the targeted medicines examined in the study. It explains how each of these treatments works and supports its findings with data from clinical trials. It also considers potential new medications and addresses persistent problems, such as resistance mechanisms, chances for combining therapies, and cutting-edge patient classification techniques. This study seeks to give healthcare professionals, researchers, and patients a thorough overview of the recent advancements in breast cancertargeted therapy by drawing on the opinions of top authorities in the area. The coordinated effort aims to create customized, efficient therapies, eventually bolstering the battle against this powerful illness.

show abstract

Section: The Function Of Monoclonal Antibodies In Breast Cancer Thera...mentioning

confidence: 99%